Wiseguyreports.Com Adds “Nuclear Medicine -Market Demand, Growth, Opportunities and Analysis Of Top Key Player Forecast To 2024” To Its Research Database
Global Nuclear Medicine is accounted for $3.50 billion in 2017 and is expected to reach $6.50 billion by 2026 growing at a CAGR of 7.1% during the forecast period. Factors such as growing demand for early & precise diagnostic methods, increasing incidence of cancer and cardiovascular disorders and huge demand for single photon emission computed tomography (SPECT) and positron emission tomography (PET) imaging are driving the market growth. However, supply deficiency, reimbursement hurdles for the manufacturer and high capital investment are restricting the growth of the growth. Moreover, rising economies, upcoming radioisotopes and increasing usage across neurological applications are providing ample opportunities for the market growth.
Nuclear medicines are used for both diagnostic and therapeutic uses and there are more than 30 specific radiopharmaceuticals used by medical practitioners. Nuclear medicine comes under the field of molecular imaging, which occupy the use of very little amount of radioactive material to detect and treat disease Several forms of nuclear medicines are required in treating cancer, neurological disorders, gastrointestinal and other diseases.
On the basis of application, therapeutic segment witnessed steady growth due to the introduction of advanced protective measures and growing awareness regarding the therapeutic procedures. By geography, North America is dominating the market during the forecasting period owing to increasing aging population, technological advancements and the presence of favorable reimbursement policies in this region.
Some of the key players in the Nuclear Medicine Market include Bayer AG, Medtronic, plc, General Electric Co., Cardinal Health, Inc., IBA Group, BWX Technologies, Australian Nuclear Science & Technology Organization (ANSTO), Mallinckrodt plc., Eckert & Ziegler Group, Lantheus Medical Imaging, Inc., Jubilant Life Sciences, Eczacibasi-Monrol Nuclear Products, Curium, Bracco Imaging S.p.A and NTP Radioisotopes SOC Ltd.
Request for Sample Report @ https://www.wiseguyreports.com/sample-request/3533741-nuclear-medicine-global-market-outlook-2017-2026
• Therapeutic Applications
• Diagnostic Applications
End Users Covered:
• Research institutes
• Hospitals and Diagnostic centers
• North America
• Asia Pacific
• South America
• Middle East & Africa
What our report offers:
– Market share assessments for the regional and country level segments
– Market share analysis of the top industry players
– Strategic recommendations for the new entrants
– Market forecasts for a minimum of 9 years of all the mentioned segments, sub segments and the regional markets
– Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
– Strategic recommendations in key business segments based on the market estimations
– Competitive landscaping mapping the key common trends
– Company profiling with detailed strategies, financials, and recent developments
– Supply chain trends mapping the latest technological advancements
Table of Content
1 Executive Summary
3 Market Trend Analysis
4 Porters Five Force Analysis
5 Global Nuclear Medicine Market, By Product
6 Global Nuclear Medicine Market, By Application
7 Global Nuclear Medicine Market, By End User
8 Global Nuclear Medicine Market, By Geography
9 Key Developments
10 Company Profiling
10.1 Bayer AG
10.2 Medtronic, plc
10.3 General Electric Co.
10.4 Cardinal Health, Inc.
10.5 IBA Group
10.6 BWX Technologies
10.7 Australian Nuclear Science & Technology Organization (ANSTO)
10.8 Mallinckrodt plc.
10.9 Eckert & Ziegler Group
10.10 Lantheus Medical Imaging, Inc.
10.11 Jubilant Life Sciences
10.12 Eczacibasi-Monrol Nuclear Products
10.14 Bracco Imaging S.p.A
10.15 NTP Radioisotopes SOC Ltd.
Contact Us: Sales@Wiseguyreports.Com Ph: +1-646-845-9349 (Us) Ph: +44 208 133 9349 (Uk)